Table 4.
Source | Design patients | n (%) | Regimens | PFS | Duration |
---|---|---|---|---|---|
McCaffrey et al. ( 56 ) | Retrospective | 56 | VeIP/VIP | 23 | 52 months |
Loehrer et al. ( 57 ) | Phase II | 135 | VeIP | 24 | 4.7 years |
Motzer et al. ( 61 ) | Phase I/II | 30 | TIP | 73 | 33 months |
Kondagunta et al. ( 62 ) | Phase II | 46 | TIP | 65 | 2 years |
Mead et al. ( 63 ) | Phase II | 51 | TIP | 38 | 1 year |
PSF, progression‐free survival; TIP, paclitaxel, ifosfamide, and cisplatin.